Study S001862

A Trial Comparing the Efficacy and Safety of Adding Liraglutide Versus Addition of Insulin Aspart With the Largest Meal to Insulin Degludec, Both in Combination With Metformin, in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification (BEGIN™: VICTOZA® ADD-ON)

ClinicalTrials.gov record

Registration

Registration: NCT01388361
Acronym: BEGIN™
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 413
Start: 2011-09
Primary completion: 2012-07
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:insulin degludec; DRUG:insulin aspart; DRUG:liraglutide
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2011-001493-25; OTHER:U1111-1120-2782

Registered primary outcomes

Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin) [week 0, week 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026175	A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Mathieu C, Diabetes, obesity & metabolism	2014	Randomized trial	PMID 24443830 DOI	registry reference RESULT:24443830